Endocrinology in Minneapolis, MN
10 verified endocrinology doctors in Minneapolis.
Endocrinologists treat hormone-related conditions such as diabetes, thyroid disorders, and metabolic disease.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Timothy Singleton, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Charles Moldow, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Jeffrey Miller, MD
Endocrinology
CMS Open Payments· $23,451 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$23,451
Total received
23
Transactions
3
Paying companies
Top paying companies
Among the 1,536 endocrinology doctors we've analyzed, about 57% received any industry payment (median $5,101 among those who did). This doctor's total ranks around the 77th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US endocrinology doctors.
Payments to Jeffrey Miller do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Philip Mcglave, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Craig Eckfeldt, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Joan Beckman, MD
Endocrinology
CMS Open Payments· $59,251 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$59,251
Total received
9
Transactions
2
Paying companies
Top paying companies
Among the 1,536 endocrinology doctors we've analyzed, about 57% received any industry payment (median $5,101 among those who did). This doctor's total ranks around the 82th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US endocrinology doctors.
Payments to Joan Beckman do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Sanjal Desai, MD
Endocrinology
CMS Open Payments· $234.79 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$234.79
Total received
2
Transactions
2
Paying companies
Top paying companies
Among the 1,536 endocrinology doctors we've analyzed, about 57% received any industry payment (median $5,101 among those who did). This doctor's total ranks around the 54th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US endocrinology doctors.
Payments to Sanjal Desai do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Jacob Cogan, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Juan Jose Chango Azanza, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Zalaya Ivy, MD
Endocrinology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.